Developmental Research Program 1

项目摘要 该淋巴瘤孢子发展研究计划的目标（DRP）是支持创新 翻译研究项目，可能在未来发展成为完整的项目。为了实现这一目标， DRP将征集在淋巴瘤和慢性淋巴细胞性白血病中具有翻译潜力的新项目 白血病（CLL）。该计划将由主任马尔科姆布伦纳博士和玛格丽特古德尔，谁 继续担任DRP领导人，新的联合领导人乔治卡鲁姆博士带来了他的临床专业知识和 致力于增加DRP获奖者的多样性。候选项目将由一个小组进行审查 具有转化研究方面的专业知识，并且最有前途的提案将被选中获得支持。我们 每个受支持项目的目标是，它将发展成为一个完整的SPORE项目或安全的同行评审 作为一个独立的项目。我们将继续实现这一目标， 将开发项目纳入SPORE，使他们能够利用SPORE的专业知识 研究人员将他们的项目从长凳上转化为床边。 在过去的四年里，我们的淋巴瘤孢子DRP支持了9个项目的广泛组合， 来自贝勒医学院五个不同部门和中心的不同研究人员， 与德克萨斯州医学中心的其他机构一样（德克萨斯A&M和莱斯大学各一个）， 全国（一个奖项给莫菲特癌症中心）。五名女性和两名任职人数不足的少数族裔调查员 在最近一个资助期内，领导了九个DRP项目，并已被利用， 从45万美元的初始投资中获得865万美元的同行评审资金。长期随访 在我们的SPORE的前两个周期资助的28个项目中，有46篇出版物被引用， 4，300倍和超过1840万美元的同行评审资金，来自140万美元的投资， 我们的DRP在与行政核心的合作中，DRP主任将继续利用这一计划， 测试和开发治疗淋巴瘤和CLL的新策略，并将收集数据以评估 DRP计划的成功，包括寻求我们内部和外部的反馈和建议 咨询委员会。

PROJECT SUMMARY The goal of the Lymphoma SPORE Developmental Research Program (DRP) is to support innovative translational research projects that may in the future develop into full projects. To achieve this objective, the DRP will solicit submission of novel projects with translational potential in lymphoma and chronic lymphocytic leukemia (CLL). The program will be led by directors Drs. Malcolm Brenner and Margaret Goodell, who continue as DRP leaders, and new co-leader Dr George Carrum who brings with him clinical expertise and a commitment to increasing diversity among DRP awardees. Candidate projects will be reviewed by a panel with expertise in translational research and the most promising proposals will be selected for support. Our goal for each supported project is that it will either develop into a full SPORE project or secure peer-reviewed funding as an independent project. We will continue to achieve this goal by fully incorporating the leaders of developmental projects into the SPORE, enabling them to take advantage of the expertise of SPORE investigators in translating their project from the bench to bedside. In the last four years, our Lymphoma SPORE DRP has supported a broad portfolio of 9 projects by diverse investigators from five different Departments and Centers within Baylor College of Medicine as well as other institutions in the Texas Medical Center (one award to Texas A&M and one to Rice University) and nationally (one award to Moffitt Cancer Center). Five female and two underrepresented minority investigators have led the nine DRP projects supported in most recent funding period and have already been leveraged to obtain $8.65 million in peer-reviewed funding from an initial investment of $450,000. Long-term follow up of the 28 projects funded in the first two cycles of our SPORE shows 46 publications that have been cited over 4,300 times and over $18.4 million dollars in peer-reviewed funding from an investment of $1.4 million through our DRP. In collaboration with the Administrative Core, the DRP directors will continue to use this program to test and develop novel strategies for the treatment of lymphoma and CLL, and will also collect data to evaluate the success of the DRP program, including seeking the feedback and advice of our internal and external advisory boards.